Anti-PEG IgG may be one of causes to induce anaphylaxis following administration of PEGylated therapeutics

Haruka Takata – Assistant Professor, Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University; Shingo Kobayashi – Associate Professor, Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University; Hidenori Ando – Associate Professor, Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University; Tatsuhiro Ishida – Professor, Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University

Introduction: We reported that an injection of PEGylated nanoparticles induces anti-PEG IgM¹⁾. Moreover, recent report showed that an injection of Covid-19 mRNA vaccine can induce not only anti-PEG IgM but also anti-PEG IgG²⁾, which may cause anaphylaxis following administration of PEGylated therapeutics. However, due to the lack of anti-PEG IgG bearing animal model, the impact of antibody class on PEGylated therapeutic-associated anaphylaxis remains unclear. Therefore, we tried to develop a mouse model bearing anti-PEG IgG to investigate the effect of anti-PEG antibodies on the anaphylaxis.